Tetsuya Mitsudomi

Summary

Affiliation: Aichi Cancer Center
Country: Japan

Publications

  1. pmc Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer?
    H Uramoto
    Cancer Chemotherapy Center, University of Occupational and Environmental Health, Japan
    Br J Cancer 96:857-63. 2007
  2. ncbi Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence
    Tetsuya Mitsudomi
    Department of Thoracic Surgery, Aichi Cancer Center Hospital, 1 1 Kanokoden, Chikusa ku, Nagoya 464 8681, Japan
    J Clin Oncol 23:2513-20. 2005
  3. ncbi Prognostic model of pulmonary adenocarcinoma by expression profiling of eight genes as determined by quantitative real-time reverse transcriptase polymerase chain reaction
    Hideki Endoh
    Department of Thoracic Surgery, Aichi Cancer Center, Hospital, 1 1 Kanokoden, Chikusa ku, Nagoya 464 8681, Japan
    J Clin Oncol 22:811-9. 2004
  4. ncbi Biological and clinical implications of EGFR mutations in lung cancer
    Tetsuya Mitsudomi
    Department of Thoracic Surgery, Aichi Cancer Center Hospital, Nagoya, 464 8681, Japan
    Int J Clin Oncol 11:190-8. 2006
  5. doi Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer
    Tetsuya Mitsudomi
    Department of Thoracic Surgery, Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, Nagoya, Japan
    FEBS J 277:301-8. 2010
  6. doi Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
    Tetsuya Mitsudomi
    Department of Thoracic Surgery, Aichi Cancer Center Hospital, Chikusa ku, Nagoya, Japan
    Lancet Oncol 11:121-8. 2010
  7. doi Advances in target therapy for lung cancer
    Tetsuya Mitsudomi
    Department of Thoracic Surgery, Aichi Cancer Center Hospital, Nagoya, Japan
    Jpn J Clin Oncol 40:101-6. 2010
  8. doi Effect of gefitinib on the survival of patients with recurrence of lung adenocarcinoma after surgery: a retrospective case-matching cohort study
    Tatsuya Katayama
    Department of Thoracic Surgery, Aichi Cancer Center Hospital, 1 1 Kanokoden, Nagoya, Japan
    Surg Oncol 19:e144-9. 2010
  9. doi Analysis of ERBB4 mutations and expression in japanese patients with lung cancer
    Kenji Tomizawa
    Department of Thoracic Surgery, Aichi Cancer Center Hospital, Nagoya, Japan
    J Thorac Oncol 5:1859-61. 2010
  10. ncbi RASSF1A gene inactivation in non-small cell lung cancer and its clinical implication
    Hideki Endoh
    Department of Thoracic Surgery, Aichi Cancer Center Hospital, Nagoya, Japan
    Int J Cancer 106:45-51. 2003

Detail Information

Publications103 found, 100 shown here

  1. pmc Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer?
    H Uramoto
    Cancer Chemotherapy Center, University of Occupational and Environmental Health, Japan
    Br J Cancer 96:857-63. 2007
    ..Through these efforts, it would be possible to individualise EGFR-TKI treatment for patients suffering from lung cancer...
  2. ncbi Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence
    Tetsuya Mitsudomi
    Department of Thoracic Surgery, Aichi Cancer Center Hospital, 1 1 Kanokoden, Chikusa ku, Nagoya 464 8681, Japan
    J Clin Oncol 23:2513-20. 2005
    ..To evaluate the relationship between mutations of the epidermal growth factor receptor (EGFR) gene and the effectiveness of gefitinib treatment in patients with recurrent lung cancer after pulmonary resection...
  3. ncbi Prognostic model of pulmonary adenocarcinoma by expression profiling of eight genes as determined by quantitative real-time reverse transcriptase polymerase chain reaction
    Hideki Endoh
    Department of Thoracic Surgery, Aichi Cancer Center, Hospital, 1 1 Kanokoden, Chikusa ku, Nagoya 464 8681, Japan
    J Clin Oncol 22:811-9. 2004
    ....
  4. ncbi Biological and clinical implications of EGFR mutations in lung cancer
    Tetsuya Mitsudomi
    Department of Thoracic Surgery, Aichi Cancer Center Hospital, Nagoya, 464 8681, Japan
    Int J Clin Oncol 11:190-8. 2006
    ..These populations precisely coincide with those populations with higher response rates to TKIs. We and others subsequently confirmed and extended these findings...
  5. doi Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer
    Tetsuya Mitsudomi
    Department of Thoracic Surgery, Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, Nagoya, Japan
    FEBS J 277:301-8. 2010
    ..The biological significance of such mutations and their relationship with other activated genes in lung cancers are also discussed...
  6. doi Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
    Tetsuya Mitsudomi
    Department of Thoracic Surgery, Aichi Cancer Center Hospital, Chikusa ku, Nagoya, Japan
    Lancet Oncol 11:121-8. 2010
    ..However, whether gefitinib is better than standard platinum doublet chemotherapy in patients selected by EGFR mutation is uncertain...
  7. doi Advances in target therapy for lung cancer
    Tetsuya Mitsudomi
    Department of Thoracic Surgery, Aichi Cancer Center Hospital, Nagoya, Japan
    Jpn J Clin Oncol 40:101-6. 2010
    ..Through these collaborations among clinicians, basic researchers and pharmaceutical companies, it should be possible to individualize lung cancer treatment to turn this fatal disease into a chronic disorder and, eventually, to cure it...
  8. doi Effect of gefitinib on the survival of patients with recurrence of lung adenocarcinoma after surgery: a retrospective case-matching cohort study
    Tatsuya Katayama
    Department of Thoracic Surgery, Aichi Cancer Center Hospital, 1 1 Kanokoden, Nagoya, Japan
    Surg Oncol 19:e144-9. 2010
    ....
  9. doi Analysis of ERBB4 mutations and expression in japanese patients with lung cancer
    Kenji Tomizawa
    Department of Thoracic Surgery, Aichi Cancer Center Hospital, Nagoya, Japan
    J Thorac Oncol 5:1859-61. 2010
    ..There was no significant difference in the clinicopathologic characteristics including prognosis of patients with high or low expression of ERBB4. The clinical significance of ERBB4 in lung cancers is negligible...
  10. ncbi RASSF1A gene inactivation in non-small cell lung cancer and its clinical implication
    Hideki Endoh
    Department of Thoracic Surgery, Aichi Cancer Center Hospital, Nagoya, Japan
    Int J Cancer 106:45-51. 2003
    ..0247). Epigenetic silencing of RASSF1A is a frequent event in non-small lung cancer and will provide novel opportunities to develop diagnosis and therapy of NSCLC...
  11. doi Subcategorization of lung cancer based on tumor size and degree of visceral pleural invasion
    Noriaki Sakakura
    Department of Thoracic Surgery, Division of Epidemiology and Prevention, Aichi Cancer Center Hospital, Nagoya, Japan
    Ann Thorac Surg 86:1084-90. 2008
    ..Lung cancer staging system proposed in 2007 adopts detailed tumor size cut-off values. Alternatively, visceral pleural invasion is deemed an important prognosticator, but has not been easily incorporated into the staging system...
  12. doi Subcategorization of resectable non-small cell lung cancer involving neighboring structures
    Noriaki Sakakura
    Department of Thoracic Surgery, Aichi Cancer Center Hospital, Nagoya, Japan
    Ann Thorac Surg 86:1076-83; discussion 1083. 2008
    ..Although the prognoses of patients with resectable lung cancer involving neighboring structures vary, the current tumor-nodes-metastasis (TNM) classification system does not elucidate criteria for tumor subcategorization...
  13. doi Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers
    Ryoichi Onozato
    Department of Thoracic Surgery, Aichi Cancer Center Hospital, Nagoya, Japan
    J Thorac Oncol 4:5-11. 2009
    ..The purpose of this study was to clarify in the role of MET activation in lung carcinogenesis...
  14. doi hOGG1 Ser326Cys polymorphism and risk of lung cancer by histological type
    Toshiki Okasaka
    Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Japan
    J Hum Genet 54:739-45. 2009
    ..These results indicate that rs1052133 contributes to the risk of adenocarcinoma of lung...
  15. doi Clinical outcomes of advanced non-small cell lung cancer patients screened for epidermal growth factor receptor gene mutations
    Kimihide Yoshida
    Department of Thoracic Oncology, Aichi Cancer Center Hospital, 1 1 Kanokoden, Chikusa ku, Nagoya, 464 8681, Japan
    J Cancer Res Clin Oncol 136:527-35. 2010
    ..To evaluate the relationship between the epidermal growth factor receptor (EGFR) mutation status and the effectiveness of gefitinib monotherapy or chemotherapy in patients with advanced non-small cell lung cancer (NSCLC)...
  16. ncbi Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib
    Kenichi Suda
    Department of Thoracic Surgery, Aichi Cancer Center Hospital, Chikusa ku, Nagoya, Japan
    J Thorac Oncol 6:1152-61. 2011
    ..However, recent clinical studies revealed that gefitinib or erlotinib are highly effective in the treatment of non-small cell lung cancer with EGFR mutations...
  17. doi Soy consumption reduces the risk of non-small-cell lung cancers with epidermal growth factor receptor mutations among Japanese
    Keitaro Matsuo
    Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, 1 1 Kanokoden, Chikusa ku, Nagoya 464 8681, Japan
    Cancer Sci 99:1202-8. 2008
    ..023). In conclusion, soy consumption may exert a protective association against the development of NSCLCs with EGFR mutations, providing possible insights into mechanisms of their genesis...
  18. doi Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib
    Tatsuya Katayama
    Department of Thoracic Surgery, Aichi Cancer Center Hospital, Chikusa ku, Nagoya, Japan
    J Thorac Oncol 4:1415-9. 2009
    ..We speculate that erlotinib, instead of high dose of gefitinib, may be also effective for the treatment of central nervous system (CNS) lesions, as trough serum concentration of erlotinib is nine times higher than that of gefitinib...
  19. ncbi Impact of one-carbon metabolism-related gene polymorphisms on risk of lung cancer in Japan: a case control study
    Takeshi Suzuki
    Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, 1 1 Kanokoden, Chikusa ku, Nagoya 464 8681, Japan
    Carcinogenesis 28:1718-25. 2007
    ..Further evaluation is warranted...
  20. doi Stepwise examination for differential diagnosis of primary lung cancer and breast cancer relapse presenting as a solitary pulmonary nodule in patients after mastectomy
    Toshiki Okasaka
    Division of Thoracic Surgery, Nagoya University Graduate School of Medicine, Showa Ku, Nagoya, Japan
    J Surg Oncol 98:510-4. 2008
    ..Definitive diagnosis of these nodules, however, is often difficult. We assessed the feasibility of our diagnostic approach for these nodules and estimated the frequency of primary lung cancer occurrence in patients after mastectomy...
  21. doi Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma
    Takayuki Kosaka
    Department of Thoracic Surgery, Aichi Cancer Center Hospital, Nagoya, Japan
    J Thorac Oncol 4:22-9. 2009
    ..We examined for EGFR, KRAS or TP53 mutations in a consecutive large cohort of patients with lung adenocarcinoma, and evaluated their prognostic impact...
  22. ncbi Risk assessment of perioperative mortality after pulmonary resection in patients with primary lung cancer: the 30- or 90-day mortality
    Kenji Tomizawa
    Department of Thoracic Surgery, Aichi Cancer Center Hospital, 1 1 Kanokoden, Chikusa ku, Nagoya, Aichi, 464 8681, Japan
    Gen Thorac Cardiovasc Surg 62:308-13. 2014
    ..Therefore, we analyzed 30- and 90-day mortality rates after pulmonary resection in patients with primary lung cancer...
  23. doi Novel metastasis-related gene CIM functions in the regulation of multiple cellular stress-response pathways
    Kiyoshi Yanagisawa
    Division of Molecular Carcinogenesis, Center for Neurological Diseases and Cancer, Nagoya University Graduate School of Medicine, Nagoya, Japan
    Cancer Res 70:9949-58. 2010
    ....
  24. doi Impact of smoking on lung cancer risk is stronger in those with the homozygous aldehyde dehydrogenase 2 null allele in a Japanese population
    Ji Young Park
    Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, 1 1 Kanokoden, Chikusa ku, Nagoya 464 8618, Japan
    Carcinogenesis 31:660-5. 2010
    ..036) and was consistently observed in the analysis among never-drinkers (interaction P = 0.041). These results suggest that ALDH2 Lys/Lys, a null enzyme activity genotype, modifies the impact of smoking on the risk of lung cancer...
  25. ncbi Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib
    Takayuki Kosaka
    Department of Thoracic Surgery, Aichi Cancer Center Hospital, 1 1 Kanokoden, Chikusa ku, Nagoya 464 8681, Japan
    Clin Cancer Res 12:5764-9. 2006
    ..Part of this "acquired resistance" is attributable to a secondary mutation resulting in threonine to methionine at codon 790 (T790M) of EGFR...
  26. ncbi Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer
    Kimihide Yoshida
    Department of Thoracic Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
    J Thorac Oncol 2:22-8. 2007
    ..We evaluated the efficacy of gefitinib monotherapy prospectively in patients with advanced or pretreated non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations...
  27. ncbi Lineage-specific dependency of lung adenocarcinomas on the lung development regulator TTF-1
    Hisaaki Tanaka
    Division of Molecular Carcinogenesis, Center for Neurological Diseases and Cancer, Nagoya University Graduate School of Medicine, Nagoya, Japan
    Cancer Res 67:6007-11. 2007
    ....
  28. doi Prognostic and predictive implications of HER2/ERBB2/neu gene mutations in lung cancers
    Kenji Tomizawa
    Department of Thoracic Surgery, Aichi Cancer Center Hospital, 1 1 Kanokoden, Chikusa ku, Nagoya 464 8681, Japan
    Lung Cancer 74:139-44. 2011
    ..However its prognostic and predictive implications are not yet established...
  29. ncbi LKB1 gene mutations in Japanese lung cancer patients
    Ryoichi Onozato
    Department of Thoracic Surgery, Aichi Cancer Center Hospital, 1 1 Kanokoden, Chikusa ku, Nagoya, Japan
    Cancer Sci 98:1747-51. 2007
    ..LKB1 gene mutations appear to be frequent in male, smoking patients of Caucasian origin, in contrast to EGFR or HER2 mutations that are frequent in non-smoking, female patients of Asian origin...
  30. doi Effect of selective lymph node dissection based on patterns of lobe-specific lymph node metastases on patient outcome in patients with resectable non-small cell lung cancer: a large-scale retrospective cohort study applying a propensity score
    Futoshi Ishiguro
    Department of Thoracic Surgery, Aichi Cancer Center Hospital, Nagoya 461 8681, Japan
    J Thorac Cardiovasc Surg 139:1001-6. 2010
    ..However, selective mediastinal lymph node dissection based on lobe-specific metastases (selective dissection) has often been performed. This study was designed to evaluate the validity of the selective lymph node dissection...
  31. ncbi Gene expression-based, individualized outcome prediction for surgically treated lung cancer patients
    Shuta Tomida
    Division of Molecular Oncology, Aichi Cancer Center Research Institute, Nagoya 464 8681, Japan
    Oncogene 23:5360-70. 2004
    ..Overall, these findings should advance not only our understanding of the biology of lung cancer but also our ability to individualize postoperative therapies based on the predicted outcome...
  32. ncbi PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients
    Hideki Endoh
    Department of Thoracic Surgery, Aichi Cancer Center Central Hospital, Nagoya, Japan
    J Thorac Oncol 1:629-34. 2006
    ..In this study, we searched for mutations or changes in the expression of genes downstream to EGFR and evaluated their relationship with the effectiveness of gefitinib...
  33. doi Clinicopathological features of small-sized non-small cell lung cancer with mediastinal lymph node metastasis
    Takayuki Fukui
    Department of Thoracic Surgery, Aichi Cancer Center Hospital, 1 1 Kanokoden, Chikusa ku, Nagoya 464 0021, Japan
    Lung Cancer 66:309-13. 2009
    ..To understand the characteristics of these aggressive tumors, we reviewed the clinicopathological features of small-sized non-small cell lung cancer patients with mediastinal lymph node metastasis resected in our institution...
  34. ncbi Risk factors differ for non-small-cell lung cancers with and without EGFR mutation: assessment of smoking and sex by a case-control study in Japanese
    Keitaro Matsuo
    Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Japan
    Cancer Sci 98:96-101. 2007
    ..In conclusion, our case-control study clearly demonstrated that the impacts of smoking and sex on the risk of EGFRmut NSCLC are different from those for EGFRwt NSCLC. Further epidemiological evaluation is warranted...
  35. doi Relationship of deregulated signaling converging onto mTOR with prognosis and classification of lung adenocarcinoma shown by two independent in silico analyses
    Hiromichi Ebi
    Division of Molecular Carcinogenesis, Center for Neurological Diseases and Cancer, Nagoya University Graduate School of Medicine, Nagoya, Japan
    Cancer Res 69:4027-35. 2009
    ..Our results clearly show the existence of gene set-definable, intrinsic heterogeneities in lung adenocarcinomas, which seem to be related to both clinical behavior and sensitivity to agents affecting the identified pathways...
  36. doi Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer
    Kenichi Suda
    Department of Thoracic Surgery, Aichi Cancer Center Hospital, 1 1 Kanokoden, Nagoya, Japan
    Clin Cancer Res 16:5489-98. 2010
    ..In this study, we explored their relationship using in vitro models and autopsy specimens...
  37. ncbi CK20 expression, CDX2 expression, K-ras mutation, and goblet cell morphology in a subset of lung adenocarcinomas
    Yasushi Yatabe
    Department of Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, Nagoya, Japan
    J Pathol 203:645-52. 2004
    ..However, some lung adenocarcinomas may express CDX2 strongly: in this case, CK20 also tends to be positive...
  38. ncbi Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications
    Takayuki Kosaka
    Departments of Thoracic Surgery and Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, Nagoya, Japan
    Cancer Res 64:8919-23. 2004
    ..EGFR mutations define a distinct subset of pulmonary adenocarcinoma without KRAS mutations, which is not caused by tobacco carcinogens...
  39. ncbi [Translational research on lung cancer--EGFR gene mutation]
    Takayuki Kosaka
    Dept of Thoracic Surgery, Aichi Cancer Center Hospital, Nagoya, Japan
    Gan To Kagaku Ryoho 32:750-8. 2005
    ..It is ultimately necessary to identify non-tobacco-related carcinogens that cause EGFR mutations for effective prevention of lung cancer...
  40. doi Impact of age on epidermal growth factor receptor mutation in lung cancer
    Tsuyoshi Ueno
    Department of Thoracic Surgery, Okayama University Hospital, Okayama, Japan
    Lung Cancer 78:207-11. 2012
    ..Positive association between EGFR mutation and age among never-smokers regardless of sex might indicate that EGFR mutation occurs cumulatively by unidentified internal/external factors other than smoking...
  41. doi Association between a genome-wide association study-identified locus and the risk of lung cancer in Japanese population
    Hidemi Ito
    Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Japan
    J Thorac Oncol 7:790-8. 2012
    ..To examine the impact of 15p25 and 5p15 on lung cancer risk and smoking intensity, we conducted a case-control study in Japanese population. We also examined whether these loci modify the effect of smoking behavior on lung cancer risk...
  42. pmc A rapid, sensitive assay to detect EGFR mutation in small biopsy specimens from lung cancer
    Yasushi Yatabe
    Department of Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, Kanokoden, Nagoya 464 8681, Japan
    J Mol Diagn 8:335-41. 2006
    ..In conclusion, the assay is a rapid, sensitive method using paraffin sections of biopsy specimens without a tumor cell-enrichment procedure and is quite useful to select a treatment of choice in clinical practice...
  43. ncbi Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients
    Hirotaka Osada
    Division of Molecular Oncology, Aichi Cancer Center Research Institute, Nagoya, Japan
    Int J Cancer 112:26-32. 2004
    ..Results of clustering analyses imply that class II HDAC genes may be regulated by a similar mechanism and deregulated during cancer development...
  44. pmc Identification of MGB1 as a marker in the differential diagnosis of lung tumors in patients with a history of breast cancer by analysis of publicly available SAGE data
    Takaomi Koga
    Department of Pathology and Molecular Diagnostics, Aichi Cancer Center Research Institute, Nagoya, Japan
    J Mol Diagn 6:90-5. 2004
    ..This suggests that MGB1 can serve as a differential molecular marker. In practice, prospective examination, using the nine cases with a history of breast cancer, confirmed the usefulness of MGB1 in differential diagnosis...
  45. ncbi Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival
    Junichi Takamizawa
    Division of Molecular Oncology, Aichi Cancer Center Research Institute, Nagoya, Japan
    Cancer Res 64:3753-6. 2004
    ..This study represents the first report of reduced expression of let-7 and the potential clinical and biological effects of such a microRNA alteration...
  46. doi Solitary pulmonary metastasis from lung cancer harboring EML4-ALK after a 15-year disease-free interval
    Kenji Tomizawa
    Department of Thoracic Surgery, Aichi Cancer Center Hospital, Nagoya, Japan
    Lung Cancer 80:99-101. 2013
    ..Based on this molecular finding, the pulmonary nodule was considered to be a recurrence after very long latent period...
  47. doi HNF4α as a marker for invasive mucinous adenocarcinoma of the lung
    Masato Sugano
    Department of Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, Nagoya, Japan
    Am J Surg Pathol 37:211-8. 2013
    ....
  48. doi Clinicoradiologic characteristics of patients with lung adenocarcinoma harboring EML4-ALK fusion oncogene
    Takayuki Fukui
    Department of Thoracic Surgery, Aichi Cancer Center Hospital, Nagoya, Japan
    Lung Cancer 77:319-25. 2012
    ..We explored the EML4-ALK gene in a relatively large cohort and reviewed the clinicoradiologic background of the patients...
  49. doi Epidermal growth factor receptor gene amplification is acquired in association with tumor progression of EGFR-mutated lung cancer
    Yasushi Yatabe
    Department of Pathology and Molecular Diagnostics, Aichi Cancer Center, Nagoya 464 8681, Japan
    Cancer Res 68:2106-11. 2008
    ..Taken together, our results show that mutation occurs early in the development of lung adenocarcinoma, and that amplification may be acquired in association with tumor progression...
  50. doi Comparison of methods for placing and managing a silastic drain after pulmonary resection
    Takayuki Fukui
    Department of Thoracic Surgery, Aichi Cancer Center Hospital, Nagoya, Japan
    Interact Cardiovasc Thorac Surg 9:645-8. 2009
    ..A BD placed using a PA approach with suction might be efficient for drainage...
  51. doi Immunohistochemical detection of EGFR mutation using mutation-specific antibodies in lung cancer
    Atsuko Kitamura
    Department of Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, Nagoya, Japan
    Clin Cancer Res 16:3349-55. 2010
    ..We used immunohistochemistry to examine recently developed antibodies specific to major hotspot mutations of L858R and DEL E746-A750...
  52. pmc Predictors of survival in patients with bone metastasis of lung cancer
    Hideshi Sugiura
    Department of Orthopaedic Surgery, Aichi Cancer Center, 1 1 Kanokoden, Chikusa ku, Nagoya, Japan
    Clin Orthop Relat Res 466:729-36. 2008
    ..The data preliminarily suggest treatment with an epithelial growth factor receptor inhibitor may improve survival after bone metastasis...
  53. ncbi Reduced expression of Dicer associated with poor prognosis in lung cancer patients
    Yoko Karube
    Division of Molecular Oncology, Aichi Cancer Center Research Institute, Nagoya, Japan
    Cancer Sci 96:111-5. 2005
    ....
  54. ncbi Serum carcinoembryonic antigen level as a surrogate marker for the evaluation of tumor response to chemotherapy in nonsmall cell lung cancer
    Futoshi Ishiguro
    Department of Thoracic Surgery, Aichi Cancer Center Hospital, Nagoya, Japan
    Ann Thorac Cardiovasc Surg 16:242-7. 2010
    ..Carcinoembryonic antigen (CEA) is a tumor marker widely used for nonsmall cell lung cancer (NSCLC). The aim of this study was to evaluate changes in serum CEA levels as a surrogate marker for tumor response to chemotherapy in NSCLC...
  55. ncbi The sensitivity of lung cancer cell lines to the EGFR-selective tyrosine kinase inhibitor ZD1839 ('Iressa') is not related to the expression of EGFR or HER-2 or to K-ras gene status
    Takeshi Suzuki
    Department of Pulmonary Medicine, Aichi Cancer Center Hospital, 1 1 Kanokoden, Chikusa ku, Nagoya 464 8681, Japan
    Lung Cancer 42:35-41. 2003
    ..These findings warrant future study to clarify how ZD1839 inhibits lung cancer cell growth and to find a useful marker for prediction of sensitivity to this novel and promising agent for the treatment of lung cancers...
  56. doi Epidermal growth factor receptor mutations in small cell lung cancer
    Akiko Tatematsu
    Department of Pathology, Aichi Cancer Center Hospital, Kanokoden, Chukusa ku, Nagoya, Japan
    Clin Cancer Res 14:6092-6. 2008
    ..According to this adenocarcinoma-specific nature of EGFR mutation, analysis of EGFR mutations with small cell lung cancers (SCLC) may provide a clue to its histogenesis...
  57. ncbi Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors
    Toshiyuki Takeuchi
    Division of Molecular Carcinogenesis, Center for Neurological Diseases and Cancer, Nagoya University Graduate School of Medicine, Nagoya, Japan
    J Clin Oncol 24:1679-88. 2006
    ..This study was conducted to gain insight into the relationship between expression profiles and underlying genetic changes, which are known to be important for the pathogenesis of lung cancers...
  58. ncbi How long should small lung lesions of ground-glass opacity be followed?
    Yoshihisa Kobayashi
    Department of Thoracic Surgery, Aichi Cancer Center Hospital, Nagoya, Japan
    J Thorac Oncol 8:309-14. 2013
    ..Pulmonary ground-glass nodules are frequently encountered. The purpose of this study was to evaluate the natural history of them and to gain some insights on how to follow them up...
  59. doi Preoperative evaluation of the depth of chest wall invasion and the extent of combined resections in lung cancer patients
    Koji Kawaguchi
    Division of Thoracic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
    Lung Cancer 64:41-4. 2009
    ..However, in patients without these findings, an extrapleural approach could be initially attempted for chest wall resection, because an en-bloc resection had no survival benefit for patients with shallow invasion...
  60. ncbi A limited association of OGG1 Ser326Cys polymorphism for adenocarcinoma of the lung
    Hidemi Ito
    Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Japan
    J Epidemiol 12:258-65. 2002
    ..This study supported the first study by Sugimura et al (Cancer Epidemiol Biomarkers Prev, 1999; 8: 669-674), that the association of OGG1 Ser326Cys polymorphism was limited for the risk of lung adenocarcinoma...
  61. ncbi Prognostic models in patients with non-small-cell lung cancer using artificial neural networks in comparison with logistic regression
    Taizo Hanai
    Department of Biotechnology, Graduate School of Engineering, Nagoya University, Chikusa ku, Nagoya 469 8603, Japan
    Cancer Sci 94:473-7. 2003
    ....
  62. ncbi A 25-signal proteomic signature and outcome for patients with resected non-small-cell lung cancer
    Kiyoshi Yanagisawa
    Institute for Advanced Research, Nagoya University, Furo cho, Chikusa ku, Nagoya, Aichi 464 8601, Japan
    J Natl Cancer Inst 99:858-67. 2007
    ..Among patients with non-small-cell lung cancer (NSCLC), those with poor prognosis cannot be distinguished from those with good prognosis...
  63. ncbi Lung cancers unrelated to smoking: characterized by single oncogene addiction?
    Kenichi Suda
    Department of Thoracic Surgery, Aichi Cancer Center Hospital, 1 1 Kanokoden, Chikusa ku, Nagoya, 464 8681, Japan
    Int J Clin Oncol 16:294-305. 2011
    ..The elucidation of the particular features of lung cancer unrelated to smoking and the development of new therapeutic modalities may reduce the mortality from lung cancers in the future...
  64. doi Conversion from the "oncogene addiction" to "drug addiction" by intensive inhibition of the EGFR and MET in lung cancer with activating EGFR mutation
    Kenichi Suda
    Department of Thoracic Surgery, Aichi Cancer Center Hospital, 1 1 Kanokoden, Chikusa ku, Nagoya, Japan
    Lung Cancer 76:292-9. 2012
    ..This series of experiments highlights the flexibility of cancer cells that have adapted to environmental stresses induced by intensive treatment with TKIs...
  65. ncbi NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism and the risk of eight cancers for Japanese
    Nobuyuki Hamajima
    Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, 1 1 Kanokoden, Chikusa ku, Nagoya 464 8681, Japan
    Int J Clin Oncol 7:103-8. 2002
    ..This study was conducted to screen possible cancer sites associated with this polymorphism by a prevalent case-control design...
  66. ncbi Decreased expression of 14-3-3sigma in neuroendocrine tumors is independent of origin and malignant potential
    Yasushi Yatabe
    Department of Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, Nagoya, Japan
    Oncogene 21:8310-9. 2002
    ....
  67. ncbi Neuroendocrine tumor metastasis to the thyroid gland
    Hiroko Yamada
    Department of Otorhinolaryngology, Nagoya University Graduate School of Medicine, Nagoya, Japan
    Int J Clin Oncol 12:63-7. 2007
    ..Head and neck surgeons should be aware that a particular subset of lung cancers may develop a metastatic solitary nodule in the thyroid, as presented. An effective therapeutic strategy is largely dependent on the differential diagnosis...
  68. doi EGFR T790M mutation: a double role in lung cancer cell survival?
    Kenichi Suda
    Department of Thoracic Surgery, Aichi Cancer Center Hospital, Chikusa ku, Nagoya, Japan
    J Thorac Oncol 4:1-4. 2009
    ..Clarification of the pathways leading to acquired resistance is essential to maximize the efficacy of EGFR-TKI therapy for patients with lung cancer...
  69. doi Prognostic evaluation based on a new TNM staging system proposed by the International Association for the Study of Lung Cancer for resected non-small cell lung cancers
    Takayuki Fukui
    Department of Thoracic Surgery, Aichi Cancer Center Hospital, Nagoya, Japan
    J Thorac Cardiovasc Surg 136:1343-8. 2008
    ..However, its validity has not been established fully. Here we assessed its utilities and drawbacks...
  70. ncbi Significant up-regulation of a novel gene, CLCP1, in a highly metastatic lung cancer subline as well as in lung cancers in vivo
    Katsumi Koshikawa
    Division of Molecular Oncology, Aichi Cancer Center Research Institute, 1 1 Kanokoden, Chikusa ku, Nagoya 464 8681, Japan
    Oncogene 21:2822-8. 2002
    ....
  71. ncbi Maspin expression in normal lung and non-small-cell lung cancers: cellular property-associated expression under the control of promoter DNA methylation
    Yasushi Yatabe
    Department of Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, Nagoya, Japan
    Oncogene 23:4041-9. 2004
    ..Separate analysis of methylation status in positive and negative portions of individual tumors provided an instance of intratumor diversity associated with promoter DNA methylation...
  72. doi Validation of a nomogram for predicting overall survival after resection of pulmonary metastases from colorectal cancer at a single center
    Yukihide Kanemitsu
    Department of Gastroenterological Surgery, Aichi Cancer Center, 1 1 Kanokoden, Chikusa ku, Nagoya, 464 8681, Japan
    World J Surg 34:2973-8. 2010
    ....
  73. doi Mutations in the epidermal growth factor receptor gene and effects of EGFR-tyrosine kinase inhibitors on lung cancers
    Takayuki Fukui
    Department of Thoracic Surgery, Aichi Cancer Center Hospital, 1 1 Kanokoden, Chikusa ku, Nagoya, 464 0021, Japan
    Gen Thorac Cardiovasc Surg 56:97-103. 2008
    ..Based on this concept, Phase III clinical trials comparing gefitinib monotherapy with standard platinum-based chemotherapy are currently ongoing for patients with EGFR mutations and lung cancer...
  74. ncbi [Postoperative adjuvant chemotherapy for lung, gastric, colorectal and breast cancers]
    Takayuki Fukui
    Department of Thoracic Surgery, Aichi Cancer Center Hospital
    Nihon Rinsho 68:1019-23. 2010
    ..In this article, we reviewed the advances and current roles of adjuvant chemotherapy in major histology of solid tumors in Japan such as lung, gastric, colorectal and breast cancers...
  75. doi Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation
    Kenichi Suda
    Department of Thoracic Surgery, Aichi Cancer Center Hospital, 1 1 Kanokoden, Chikusa ku, Nagoya, 464 8681, Japan
    Cancer Metastasis Rev 29:49-60. 2010
    ..In this review, we describe the features of KRAS mutations in lung cancer and contrast these with the features of EGFR mutations. Recent strategies to combat lung cancer harboring KRAS mutations are also reviewed...
  76. ncbi Significance of the number of positive lymph nodes in resected non-small cell lung cancer
    Takayuki Fukui
    Department of Thoracic Surgery, Aichi Cancer Center Hospital, Nagoya, Japan
    J Thorac Oncol 1:120-5. 2006
    ..In this study, we evaluated the prognostic significance of the number of positive lymph nodes in resected non-small cell lung cancer...
  77. ncbi [Gefitinib and epidermal growth factor receptor gene mutation]
    Takayuki Fukui
    Dept of Thoracic Surgery, Aichi Cancer Center Hospital, Japan
    Gan To Kagaku Ryoho 34:1168-72. 2007
    ..Based on this concept, phaseIII clinical trials comparing gefitinib monotherapy with standard platinum-based chemotherapy in lung cancer patients with EGFR mutations are ongoing...
  78. ncbi Aberrant hypermethylation of the CHFR prophase checkpoint gene in human lung cancers
    Kotaro Mizuno
    Division of Molecular Oncology, Aichi Cancer Center Research Institute, 1 1 Kanokoden, Chikusa ku, Nagoya 464 8681, Japan
    Oncogene 21:2328-33. 2002
    ..This is the first description of aberrant hypermethylation of the CHFR gene in any type of human cancer, and provides further evidence of the involvement of multiple checkpoint alterations in lung cancer...
  79. ncbi Epidermal growth factor receptor mutations in lung cancers
    Yasushi Yatabe
    Department of Pathology and Molecular Diagnostics, Aichi Cancer Center, Nagoya, Japan
    Pathol Int 57:233-44. 2007
    ..In the present study the current knowledge of EGFR mutations is reviewed, insights from which raise many further questions, and thus suggest new directions for future research...
  80. ncbi Controversy about small peripheral lung adenocarcinomas: how should we manage them?
    Takayuki Fukui
    Department of Thoracic Surgery, Aichi Cancer Center Hospital, Nagoya, Japan
    J Thorac Oncol 2:546-52. 2007
    ....
  81. doi Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma
    Yasushi Yatabe
    Department of Pathology and Molecular Diagnostics, Aichi Cancer Center, 1 1 Kanokoden, Chikusa ku, Nagoya 464 8681, Japan
    J Clin Oncol 29:2972-7. 2011
    ..Some studies have shown that epidermal growth factor receptor (EGFR) mutations can be heterogeneously distributed in individual tumors. In this study, we re-evaluated the distribution of EGFR mutations within tumors...
  82. ncbi Interferon-gamma differentially regulates susceptibility of lung cancer cells to telomerase-specific cytotoxic T lymphocytes
    Kouhei Tajima
    Division of Immunology, Aichi Cancer Center Research Institute, Nagoya, Japan
    Int J Cancer 110:403-12. 2004
    ....
  83. pmc EGFR mutations in patients with brain metastases from lung cancer: association with the efficacy of gefitinib
    Shinji Shimato
    Department of Neurosurgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
    Neuro Oncol 8:137-44. 2006
    ..Gefitinib appears to be effective in treating brain metastases in a subgroup of patients. Our data suggested a possible association between the efficacy of gefitinib in the treatment of brain metastases and EGFR mutations...
  84. ncbi Gene-environment interactions between the smoking habit and polymorphisms in the DNA repair genes, APE1 Asp148Glu and XRCC1 Arg399Gln, in Japanese lung cancer risk
    Hidemi Ito
    Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya Aichi, Japan
    Carcinogenesis 25:1395-401. 2004
    ..936) and that with light smoking was 2.67 (95% CI 1.00-7.68, P = 0.049). These results suggest that APE1 Asp148Glu and XRCC1 Arg399Gln polymorphisms might modify the risk of lung cancer attributable to cigarette smoking exposure...
  85. ncbi TTF-1 expression in pulmonary adenocarcinomas
    Yasushi Yatabe
    Department of Anatomic and Molecular Diagnostic Pathology, Aichi Cancer Center Hospital, Aichi Cancer Center Research Institute, Nagoya, Japan
    Am J Surg Pathol 26:767-73. 2002
    ..01), less frequent RB loss (p <0.05), and preserved expression of p27 (p <0.01). The results supported the TTF-1 lineage marker and suggested that molecular pathogenesis may in part be characterized by cellular lineage...
  86. ncbi EGFR mutation is specific for terminal respiratory unit type adenocarcinoma
    Yasushi Yatabe
    Department of Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, Nagoya, Japan
    Am J Surg Pathol 29:633-9. 2005
    ..These findings further confirm that TRU-type-adenocarcinoma is a distinct adenocarcinoma subset in which a particular molecular pathway is involved...
  87. ncbi Mutations of epidermal growth factor receptor and K-ras genes in adenosquamous carcinoma of the lung
    Shinichi Toyooka
    Int J Cancer 118:1588-90. 2006
  88. ncbi Polymorphism of dihydropyrimidine dehydrogenase (DPYD) Cys29Arg and risk of six malignancies in Japanese
    Daisuke Tanaka
    Department of Preventive Medicine Biostatistics and Medical Decision Making, Nagoya University Graduate School of Medicine, Japan
    Nagoya J Med Sci 67:117-24. 2005
    ..52 (0.71-3.28) and 0.31 (0.71-1.34), respectively. Although prevalent cases were used, this study suggested that the influence of DPYD T85C posed only a limited risk for the six malignancies...
  89. ncbi EGFR mutation and response of lung cancer to gefitinib
    Shinichi Toyooka
    N Engl J Med 352:2136; author reply 2136. 2005
  90. ncbi The effect of gefitinib on B-RAF mutant non-small cell lung cancer and transfectants
    Shinichi Toyooka
    Department of Cancer and Thoracic Surgery, Graduate School of Medicine, Okayama University, Okayama, Japan
    J Thorac Oncol 2:321-4. 2007
    ..However, our in vitro investigation did not explain the response observed in this particular patient. Further investigation is necessary to elucidate the mechanism of tumor sensitivity to EGFR tyrosine kinase inhibitors...
  91. ncbi Throwing new light on lung cancer pathogenesis: updates on three recent topics
    Shuta Tomida
    Division of Molecular Oncology, Aichi Cancer Center Research Institute, Aichi, Japan
    Cancer Sci 96:63-8. 2005
    ..Second, we deal with EGFR mutations, which shows revealing specificities in various aspects. Finally, advances in the expression profiling analysis of both transcriptomes and proteomes of lung cancers are summarized...
  92. ncbi Association of a polymorphism of the phospholipase D2 gene with the prevalence of colorectal cancer
    Yoshiji Yamada
    Department of Gene Therapy, Gifu International Institute of Biotechnology, 2193 128 Mitake, 505 0116, Gifu, Japan
    J Mol Med (Berl) 81:126-31. 2003
    ..These results suggest that the phospholipase D(2) gene is a susceptibility locus for colorectal cancer in Japanese individuals, although a functional effect of the 1814C-->T (Thr577Ile) polymorphism was not detected...
  93. ncbi [Molecular targeted therapy--non-small-cell lung cancer and gefitinib]
    Junichi Shimizu
    Dept of Thoracic Oncology, Aichi Cancer Center Central Hospital
    Gan To Kagaku Ryoho 32:1879-85. 2005
    ....
  94. ncbi MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
    Jeffrey A Engelman
    Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
    Science 316:1039-43. 2007
    ..Thus, we propose that MET amplification may promote drug resistance in other ERBB-driven cancers as well...
  95. ncbi Analysis of beta-tubulin gene alteration in human lung cancer cell lines
    Hiroyuki Achiwa
    Department of Internal Medicine and Molecular Science, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho cho, Mizuho ku, Nagoya 467 8601, Japan
    Cancer Lett 201:211-6. 2003
    ..In addition, the presence of a closely related family of beta-tubulins or pseudogenes was thought to hinder accurate evaluation of the beta-tubulin gene...
  96. ncbi Different risk relations with smoking for non-small-cell lung cancer: comparison of TP53 and TP73 genotypes
    Akio Hiraki
    Department of Respiratory Medicine, National Sanyo Hospital, Yamaguchi, Japan
    Asian Pac J Cancer Prev 4:107-12. 2003
    ..The association between TP53/TP73 gene polymorphisms and tobacco smoking was evaluated with regard to risk of non-small cell lung cancer (NSCLC)...
  97. ncbi [Molecular diagnosis in lung cancer]
    Tetsuya Mitsudomi
    Department of Thoracic Surgery, Aichi Cancer Center Hospital
    Nihon Rinsho 60:233-7. 2002
  98. pmc Increased prevalence of EGFR-mutant lung cancer in women and in East Asian populations: analysis of estrogen-related polymorphisms
    Daphne W Bell
    Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, Massachusetts 02129, USA
    Clin Cancer Res 14:4079-84. 2008
    ....
  99. doi Epidermal growth factor receptor mutation, but not sex and smoking, is independently associated with favorable prognosis of gefitinib-treated patients with lung adenocarcinoma
    Shinichi Toyooka
    Department of Cancer and Thoracic Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, 2 5 1 Shikata cho, Okayama 700 8558, Japan
    Cancer Sci 99:303-8. 2008
    ....
  100. doi Phase II trial of preoperative chemoradiotherapy followed by surgical resection in patients with superior sulcus non-small-cell lung cancers: report of Japan Clinical Oncology Group trial 9806
    Hideo Kunitoh
    Department of Medical Oncology, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
    J Clin Oncol 26:644-9. 2008
    ..To evaluate the safety and efficacy of preoperative chemoradiotherapy followed by surgical resection for superior sulcus tumors (SSTs)...
  101. ncbi The impact of sex and smoking status on the mutational spectrum of epidermal growth factor receptor gene in non small cell lung cancer
    Shinichi Toyooka
    Department of Cancer and Thoracic Surgery, Okayama University, Okayama, Japan
    Clin Cancer Res 13:5763-8. 2007
    ..In this study, we extensively investigated the impact of sex and smoking on the EGFR mutation...